Clinical Trials
234 trialsNCT05027425 2026-05-06
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Terminated
NCT05718882 2026-04-30
Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
RenJi Hospital
Phase NA Terminated
NCT05103904 2026-04-24
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Phase 2 Terminated
NCT03727633 2026-03-31
LIDA-BII
University Hospital, Montpellier
Phase 2 Terminated
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT02439008 2026-03-13
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
Centre Oscar Lambret
Phase NA Terminated
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT06851104 2026-02-18
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Guangxi Medical University
Phase 2 Terminated
NCT04258566 2026-02-02
Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies
National Institutes of Health Clinical Center (CC)
Phase NA Terminated
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT04805788 2025-12-31
Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer
Mayo Clinic
Phase 2 Terminated
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT02881554 2025-10-29
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
University of Washington
Phase NA Terminated
NCT05220722 2025-10-23
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
Phase 1/2 Terminated
NCT05229601 2025-10-22
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Terminated
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
NCT05199285 2025-10-03
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Academic and Community Cancer Research United
Phase 2 Terminated
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT06302400 2025-09-19
RHEPaiR
Imperial College London
Phase NA Terminated
NCT05582018 2025-09-15
PANORAMA
Techsomed Medical Technologies LTD
Phase NA Terminated
NCT04502082 2025-09-08
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT04989387 2025-09-02
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05451862 2025-08-26
HOMIE-166
Terumo Europe N.V.
Phase NA Terminated
NCT03316872 2025-07-25
Study of Pembrolizumab and Radiotherapy in Liver Cancer
University Health Network, Toronto
Phase 2 Terminated
NCT04116320 2025-07-14
AM-003
University of Virginia
Phase 1 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT04520906 2025-07-01
To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
Suzhou Hengruihongyuan Medical Technology Co. LTD
Phase NA Terminated
NCT03534141 2025-05-16
MHALT
University of California, San Francisco
Phase NA Terminated
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT05757492 2025-05-01
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Terminated
NCT05448677 2025-04-20
ABE-LIVER
University Hospital, Grenoble
Phase 2 Terminated
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT03889093 2025-03-24
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
University of Minnesota
Phase NA Terminated
NCT04629339 2025-03-13
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
Phase 2 Terminated
NCT05137899 2025-03-11
ADVANCE HCC
Ontario Clinical Oncology Group (OCOG)
Phase 2 Terminated
NCT05770882 2025-03-11
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Great Novel Therapeutics Biotech & Medicals Corporation
Phase 1/2 Terminated
NCT03812289 2025-03-07
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
OHSU Knight Cancer Institute
Phase NA Terminated
NCT06848556 2025-02-27
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
Zhejiang Raygene Pharmaceuticals Co., Ltd
Phase 1/2 Terminated
NCT05909995 2025-02-18
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT01205828 2025-02-12
ABT-888 and Temozolomide for Liver Cancer
Georgetown University
Phase 2 Terminated
NCT05497453 2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2 Terminated
NCT05776875 2025-01-15
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Yale University
Phase 2 Terminated
NCT05653427 2025-01-13
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 2 Terminated